Pfizer's smoking-cessation drug Chantix was linked to a 72% increase in cardiovascular problems, including stroke and congestive heart failure, according to a new analysis of medical studies.
WSJ.com: What's News US, Wall Street Journal
Mon, 07/04/2011 - 9:00am
Pfizer's smoking-cessation drug Chantix was linked to a 72% increase in cardiovascular problems, including stroke and congestive heart failure, according to a new analysis of medical studies.